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Abstract
Background: Deletions within the short arm of chromosome 7 are observed in approximately 25% of adult and
10% of Wilms pediatric renal tumors. Within Wilms tumors, the region of interest has been delineated to a 2-Mb
minimal region that includes ten known genes. Two of these ten candidate genes, SOSTDC1 and MEOX2,a r e
particularly relevant to tumor development and maintenance. This finding, coupled with evidence that SOSTDC1 is
frequently downregulated in adult renal cancer and regulates both Wingless-Int (Wnt)- and bone morphogenetic
protein (BMP)-induced signaling, points to a role for SOSTDC1 as a potential tumor suppressor.
Methods: To investigate this hypothesis, we interrogated the Oncomine database to examine the SOSTDC1 levels
in adult renal clear cell tumors and pediatric Wilms tumors. We then performed single nucleotide polymorphism
(SNP) and sequencing analyses of SOSTDC1 in 25 pediatric and 36 adult renal tumors. Immunohistochemical
staining of patient samples was utilized to examine the impact of SOSTDC1 genetic aberrations on SOSTDC1
protein levels and signaling.
Results: Within the Oncomine database, we found that SOSTDC1 levels were reduced in adult renal clear cell
tumors and pediatric Wilms tumors. Through SNP and sequencing analyses of 25 Wilms tumors, we identified four
with loss of heterozygosity (LOH) at 7p and three that affected SOSTDC1. Of 36 adult renal cancers, we found five
with LOH at 7p, two of which affected SOSTDC1. Immunohistochemical analysis of SOSTDC1 protein levels within
these tumors did not reveal a relationship between these instances of SOSTDC1 LOH and SOSTDC1 protein levels.
Moreover, we could not discern any impact of these genetic alterations on Wnt signaling as measured by altered
beta-catenin levels or localization.
Conclusions: This study shows that genetic aberrations near SOSTDC1 are not uncommon in renal cancer, and
occur in adult as well as pediatric renal tumors. These observations of SOSTDC1 LOH, however, did not correspond
with changes in SOSTDC1 protein levels or signaling regulation. Although our conclusions are limited by sample
size, we suggest that an alternative mechanism such as epigenetic silencing of SOSTDC1 may be a key contributor
to the reduced SOSTDC1 mRNA and protein levels observed in renal cancer.
Background
Renal tumors affecting both adults and children are often
idiopathic in origin. The clinical presentation, disease his-
tory, and treatments of renal tumors differ between chil-
dren and adults. In children, the majority of renal masses
are pediatric Wilms tumors. Wilms tumor is the sixth
most common malignancy of childhood, annually affecting
approximately 500 children in the United States [1]. While
lesions respond quite well to treatment, with an overall
survival rate of 85% [2], the challenge remains to identify
disease subtypes so that high risk patients are sufficiently
addressed while low risk patients are not overtreated.
Compared to pediatric Wilms tumors, adult renal can-
cers tend to be more difficult to detect and respond
more poorly to treatment. Incidence of adult renal carci-
noma has increased steadily since the 1970’s[ 3 ] .T h e
most prevalent type of adult renal tumor is renal clear
cell carcinoma (RCC-clear), which accounts for 80-85%
of adult renal cancer cases. Less common adult lesions
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lary, and oncocytic (< 5%) types.
Genes found within regions of loss of heterozygosity
(LOH) associated with both pediatric and adult renal
cancers represent candidate tumor suppressors whose
inactivation may be critical for the initiation or progres-
sion of renal cancer. In both pediatric and adult tumors,
cytogenetic changes have been noted on the short arm
of chromosome 7. Within Wilms tumors, these include
a 10% incidence of LOH on 7p [4]. Likewise, loss of 7p,
duplication of 7q, and consistent gains of chromosome
7 have been identified in adult late stage RCC-clear and
RCC-papillary subtypes [5-9].
In Wilms tumors, a consensus region of LOH has
been identified within 7p21 containing ten known genes,
including two candidate tumor suppressor genes,
mesenchyme homeobox 2 (MEOX2) and sclerostin
domain containing 1 (SOSTDC1) [10]. The mesenchyme
homeobox 2 protein is a transcription factor that inhi-
bits vascular endothelial cell proliferation and angiogen-
esis by upregulating p21 expression and decreasing NF-
B activity [11]. SOSTDC1 encodes a secreted signaling
modulator that is known to affect signaling by bone
morphogenic proteins (BMPs) and Wingless-Int (Wnt)
l i g a n d s[ 1 2 - 1 4 ] .P r e v i o u sf i n d i n g sd e m o n s t r a t e dt h a t
SOSTDC1 is abundantly expressed in the renal epithelia
of the distal tubules, collecting ducts, and urothelium
[15] and that it is downregulated in adult renal carcino-
mas [16]; however, the association between LOH at
SOSTDC1 and adult renal cancer has not been explored.
The capacity for SOSTDC1 to regulate two key signal-
ing pathways, BMP and Wnt, in renal cells make it of
particular interest as a potential renal tumor suppressor
[16]. As changes in BMP signaling have been noted in a
variety of tumors [17-19], including renal tumors [20], an
extracellular modulator of BMP signaling could have
potential tumor suppressor roles within normal kidney
epithelia. Similarly, dysregulation of the Wnt pathway
often plays a role in tumorigenesis [21]. In Wilms tumors
specifically, mutations have been observed in b-catenin,
the main intracellular effector of classical Wnt signaling
[22]. Alterations in Wnt signaling have also been impli-
cated in adult renal carcinoma [23]. The observations
that SOSTDC1 is located within a chromosomal region
frequently disrupted in renal tumors and that the
SOSTDC1 protein modifies two cell signaling pathways
that are critical to renal development and function, led us
to investigate the relationship between LOH at 7p and
SOSTDC1 in adult as well as pediatric kidney tumors.
Methods
Cells and culture conditions
The HEK-293 (CRL-1573; human embryonic kidney),
MDA-MB-231 (HTB-26; epithelial adenocarcinoma),
and MCF-10A (CRL-10317; mammary epithelial) cell
lines were maintained as recommended by American
Type Culture Collection (ATCC).
Collection of tissues
Approval was obtained from the Institutional Review
Board at Wake Forest University for the retrieval of
matched normal and tumor tissues from the Tumor
Bank of the Wake Forest University Comprehensive
Cancer Center. Matched normal and tumor tissues were
collected for 36 adult kidney cancer patients and seven
pediatric Wilms tumor patients. Information concerning
the patients’ primary diagnoses was collected; however,
no patient identifiers were obtained. An additional 18
matched normal and Wilms tumor tissues were
obtained from the Cooperative Human Tissue Network
(CHTN), which is funded by the National Cancer Insti-
tute. Other investigators may have received portions of
these tissue samples. Patient diagnostic and treatment
information were made available for each tissue. Tissues
were collected as snap frozen specimens stored at -80°C.
Sample preparation and genomic DNA isolation
Each snap frozen tissue was sectioned on a bed of dry ice
to ensure minimal thawing during sample preparation. An
approximately 30-50 mg piece of tissue was cut and an
adjacent piece of tissue was removed for formalin fixation
and paraffin embedding for subsequent histological pro-
cessing. Genomic DNA was isolated from tissue samples
via homogenization in ice cold lysis buffer [10 mM Tris
pH 8.0, 0.1 M ethylenediaminetetraacetic acid (EDTA),
0.5% sodium dodecyl sulfate (SDS), 100 μg/mL Proteinase
K, 25 μg/mL RNAase]. Subsequent phenol-chloroform
extraction was carried out as previously described [24].
Integrity and concentration of each resulting DNA sample
was assessed by agarose gel electrophoresis.
Sequencing primer design
The known coding region of SOSTDC1 is contained
within two exons. Other potentially transcribed areas
have been identified in the University of California
Santa Clara Genome database [25-27]. Two of these
potential exons occur upstream of the coding region
and an additional exon occurs between the known cod-
ing exons for a total of five putative exons or regulatory
regions at this locus (see Additional file 1). Primers
were designed for direct sequencing for a total of 13
pairs of direct sequencing primers (see Additional file
2). All primers were synthesized by Integrated DNA
Technologies (IDT).
PCR amplification and direct sequencing
Each direct sequencing primer pair was used to amplify
all five putative regions of interest in each normal and
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reactions using 60 ng of genomic DNA, 15 pmol of
both the forward and reverse primer, 4-5U of Taq poly-
merase (Life Technologies), 1.5 mM MgCl2, 200 μM
dNTPs. Depending on prior reaction optimization, gen-
eral cycling conditions were: 94°C 4 min, followed by
25-30 cycles at 94°C for 1 min, Tanneal for 1 min, and at
72°C for 1 min; and finishing with a single extension
cycle at 72°C for 5 min. PCR products were purified
using the Quickstep 96-well PCR purification kit (Edge
Biosystems). DNA sequencing was performed using the
ABI BigDye Terminator sequencing kit (Applied Biosys-
tems, Inc.) Each 10 μL sequencing reaction contained
10-50 ng of purified PCR product, 1.5 pmoles of
sequencing primer, 1 μL of BigDye Terminator mix, 1.5
μL of 5 × sequencing dilution buffer (400 mM Tris pH
9.0, 10 mM MgCl2) and water to volume. Cycling condi-
tions were 94°C for 1 min; 25 cycles at 94°C for 30 sec,
50°C for 30 sec, and 60°C for 4 min; and finishing with
a single 72°C extension step for 5 min. The sequencing
reactions were run on an ABI 3730XL DNA sequencer
and data were analyzed using Sequencher software
(GeneCodes, Version 4.7).
Loss of heterozygosity analysis
To examine the area surrounding SOSTDC1 for loss of
heterozygosity, single nucleotide polymorphisms (SNPs)
were genotyped. Fifty-one SNPs within the 2.4 Mb
region with high percentages of heterozygosity (> 0.45)
were chosen for analysis (HapMap) [28]. Primers for
each SNP were designed for analysis on the MassAR-
RAY system (Sequenom; see Additional file 3). All pri-
mers were synthesized by IDT. The genotyping
reactions were performed with 5 ng genomic DNA from
each sample.
Immunohistochemical analysis of patient samples
Formalin-fixed, paraffin-embedded renal tissue samples
analyzed for LOH were sectioned and processed for
immunohistochemistry as previously described [28]. Tis-
sues were stained with anti-b-catenin antibody (BD
Transduction Laboratories) or SOSTDC1-specific rabbit
antiserum [16]. Primary antibody treatments were fol-
lowed by incubation with ImmPRESS anti-mouse/rabbit
or anti-rabbit IgG peroxidase-conjugated secondary anti-
bodies (Vector Laboratories) and development with 3,3’-
diaminobenzidine (DAB; Vector Laboratories). Stained
sections were imaged using a Zeiss Axioplan2 confocal
microscope (Carl Zeiss, Inc.).
Antibody characterization
Antibody specificity was verified in four ways (see
Additional file 4). First, we verified that immunohisto-
chemical staining of tissues was not observed in the
absence of SOSTDC1 antiserum. Second, we confirmed
that the antiserum detected recombinant SOSTDC1
protein. Known quantities of glutathione S-transferase
(GST)-tagged SOSTDC1 protein (Novus Biologicals)
were gel-resolved, transferred to nitrocellulose, and
immunoblotted with SOSTDC1-specific antiserum as
described previously [16]. Third, antibody specificity
was confirmed by peptide competition. Cells were
lysed in Triton X-100 lysis buffer [50 mM Tris pH 7.5,
150 mM sodium chloride, 0.5% Triton X-100 (Sigma)]
containing Complete protease and phosSTOP phos-
phatase inhibitor cocktail tablets (Roche Diagnostics).
After protein electrophoresis, transfer, and blocking,
duplicate membranes were immunoblotted with
SOSTDC1-specific antiserum in the presence or
absence of the immunizing peptide (Ac-CVQHHRERK-
RASKSSKHSMS-OH; Biosource) at a concentration of
1 μg/mL. Protein detection then proceeded as
described previously [16]. Equal protein loading was
verified by immunoblotting with anti-glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) antibody (Fitzger-
ald). Fourth, we confirmed that FLAG-tagged
SOSTDC1 that had been immunoprecipitated by anti-
FLAG antibody (M2; Sigma-Aldrich) was detected by
our antibody.
Results
SOSTDC1 expression levels in renal carcinoma
We had previously observed that SOSTDC1 expression
is decreased in adult renal carcinomas [16]. To assess
whether expression levels of SOSTDC1 were similarly
decreased in pediatric kidney cancer patients, we quer-
ied the Oncomine database [29]. The sample size and
expression sensitivity of this method improved the
likelihood of detecting a notable change in SOSTDC1
that correlated with development of renal tumors.
Consistent with a potential role for SOSTDC1 as a
tumor suppressor, SOSTDC1 expression was statisti-
cally significantly decreased in both adult clear cell
renal carcinoma and pediatric Wilms tumors. As
shown in Figure 1, there is a significant reduction in
SOSTDC1 in Wilms tumors and renal clear cell carci-
noma. The median value of SOSTDC1 expression in
normal adult tissue was 1.13 and that in normal fetal
tissue was 4.00, while the levels of SOSTDC1 expres-
sion in adult renal clear cell carcinoma and pediatric
Wilms tumors were significantly lower, at -1.00 and
-2.92, respectively (p < 0.001).
Loss of heterozygosity at 7p21 within pediatric Wilms
tumors
To test whether the reduced SOSTDC1 expression
could be attributed to genetic losses at 7p, we per-
formed a SNP and sequencing analysis of SOSTDC1 in
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tumors, SNP genotyping over the 2.4 Mb region at
7p21.1 to 7p21.2 revealed LOH in three of the 25
tumors (Figure 2; patient numbers W-733, W-8188, and
W-8194). These LOH-containing samples included a
patient with hemihypertrophy being evaluated for Beck-
width-Wiedemann syndrome with a Stage II tumor that
showed complete LOH at every informative SNP in the
region (Patient W-733); a patient with a multifocal
Wilms tumor also showing complete LOH at every
informative SNP (W-8188); and a patient with anaplastic
Wilms (W-8194), showing one instance of LOH at SNP
rs6942413, near MEOX2.
Direct sequencing of the SOSTDC1 allele revealed one
additional patient, W-8197, with one instance of LOH
affecting the 3’ untranslated region (UTR) in exon 5 of
SOSTDC1; all other sequences in this patient showed no
informative SNPs. Direct sequencing also confirmed that
LOH directly affects SOSTDC1 in patients W-733 and
W-8188, as every heterozygous SNP in the normal was
lost in the tumor (Table 1). Patient W-8194 had no
informative SNPs seen in the direct sequence of
SOSTDC1, so it was not possible to ascertain whether
this patient exhibited LOH at SOSTDC1. Sequence ana-
lysis revealed no mutations within known exons (3 and
5) or candidate exons (1, 2, and 4) of the remaining
SOSTDC1 allele.
Loss of heterozygosity at 7p21 in adult renal tumors
Three of the 36 adult patients samples analyzed showed
LOH in the 2.4 Mb region of interest (Figure 2). Two of
these patients had clear cell renal carcinoma (RCC-1
and RCC-614); while one had a less common oncocy-
toma (RCC-635). Patient RCC-614 showed LOH over
much of the area, while RCC-1 and RCC-635 showed
LOH at approximately 15-20% of informative SNPs.
Direct sequencing of SOSTDC1 exons in adult tumors
also showed LOH in patients RCC-614 and RCC-635 in
several locations of exon 1 (Table 1). Additionally,
patients RCC-129 and RCC-737 also showed LOH in
one SNP each.
The adult tumors displaying LOH did so at some but
not all loci, even within the SOSTDC1 gene itself. This
is in contrast to what was observed within the Wilms
tumors, where the samples with LOH displayed com-
plete LOH at every heterozygous allele. Among all sam-
ples (adult and pediatric), LOH within SOSTDC1 was
observed mostly in the putative exon 1, with no
observed heterozygosity loss in the regions of the gene
that are known to be transcribed. Whether adult or
Wilms, for each SNP that showed LOH in more than
one sample, the same allele was lost. For example, at the
beginning of exon 1 (position 16,536,641) the G is
absent from the C/G in RCC-614, RCC-635 (Table 1).
Impact of SOSTDC1 LOH on protein expression
We hypothesized that SOSTDC1 LOH might lead to
decreased protein expression in the RCC and Wilms
tumor samples. To address this possibility, the
SOSTDC1 protein expression of tumor samples with
and without LOH at SOSTDC1 was analyzed by immu-
nohistochemistry. Antiserum from rabbits immunized
with a peptide corresponding to the 18 C-terminal
amino acids of the SOSTDC1 protein was used for this
analysis. The antiserum has been used previously in an
immunohistochemical application and additional charac-
terization is included ([16]; see Additional file 4).
When tumor samples were stained for SOSTDC1, the
protein showed defined perinuclear and diffuse cytosolic
localization in both adult and pediatric renal tumors.
Representative images are shown in Figure 3. SOSTDC1
expression was not markedly reduced within tumor
samples with SOSTDC1 LOH in either Wilms tumors
or RCC [compare Wilms -LOH (W-8178) to Wilms
+ L O H( W - 7 3 3 )i nF i g u r e3 Aa n da d u l tr e n a lt u m o r s
-LOH (RCC-347) to +LOH (RCC-614) in Figure 3B].
Other samples with SOSTDC1 LOH similarly exhibited
no observable variations in SOSTDC1 protein expres-
sion or localization. As the SOSTDC1-specific LOH in
these samples was largely in the putative or regulatory
exon 1 (Table 1), this observation is not necessarily
unexpected.
Figure 1 Oncomine database shows significant SOSTDC1
downregulation in adult renal clear cell tumors and pediatric
Wilms tumors. The Oncomine database was queried for all studies
involving markers in SOSTDC1 (data queried on 11/08/2010). Results
of five studies were compared using the software available on the
site [40-44]. Dots above and below the boxes show sample
maximum and minimum values, respectively. The horizontal lines
show the spread of the values from starting at the 10% value
through the 90% value, with the box highlighting the range of 25%
to 75%. Dark boxes show the normal or control tissues for each
study and white boxes show adult clear cell renal carcinoma and
Wilms tumor values. The horizontal black bar through each box
shows the median value for the sample. ** p < 0.001, normal adult
or fetal renal tissue compared to adult RCC or Wilms tumors.
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Given that LOH at SOSTDC1 may lead to protein
reductions that would be too subtle to be detected by
immunohistochemistry and no obvious reductions in
SOSTDC1 levels were observed in patient samples, we
examined effects of LOH at SOSTDC1 on Wnt signal-
ing. The likelihood that signaling might amplify the
effects of SOSTDC1 variations increased the possibility
for detection. We hypothesized that SOSTDC1 LOH
would decrease the protein’s abrogation of Wnt-induced
signaling, resulting in increased b-catenin stability and/
or nuclear localization.
To analyze the effect of SOSTDC1 LOH on cell signal-
ing in pediatric Wilms tumors, patient samples with or
w i t h o u tL O Hw e r es t a i n e dw i t hab-catenin-specific
antibody. As shown in Figure 3A, the b-catenin localized
largely to the cell periphery in the pediatric tumor sam-
ples. The LOH status of the samples did not correspond
with obvious changes in b-catenin levels and localization
[Figure 3A, compare -LOH (tumor W-8181) to the
+LOH sample (W-733)].
Adult renal carcinoma samples with and without LOH
at SOSTDC1 were also examined for changes in Wnt
signaling via immunohistochemistry. As in the pediatric
renal tumors, the b-catenin localized largely to the cell
membrane. LOH-specific alterations in b-catenin were
not evident in the adult renal cell tumors. [Figure 3B,
compare the -LOH sample (RCC-377) to sample with
SOSTDC1 LOH (RCC-1)]. Thus, in the patient samples
we examined, SOSTDC1 L O Hw a sn o ta s s o c i a t e dw i t h
consistent or strong changes in Wnt-induced signaling.
Discussion
The frequency of deletions within the short arm of
chromosome 7 in adult and pediatric renal tumors high-
lights the possibility that this region may contain genes
that encode renal tumor suppressors. Evidence from
Wilms tumors has narrowed the region of interest on
chromosome 7 to a 2-Mb region within 7p21 that con-
tains ten known genes, including SOSTDC1 [10]. Obser-
v a t i o n st h a tS O S T D C 1i se x p r e s s e di nn o r m a lr e n a l
tissue and that its expression is decreased in renal
Figure 2 LOH analysis in 2.4 Mb region of chromosome 7p. Results from LOH-containing pediatric Wilms (W) and adult renal carcinoma
(RCC) samples are aligned with a 7p21.1 to 7p21.2 SNP map. Patient identifiers are shown on the right; RCC denotes adult renal cell carcinoma
and W denotes Wilms tumors. Only those patients exhibiting LOH are shown. The 51 SNP markers used in this study are shown along the
bottom. They are mapped according to their physical location from 15400000 to 18000000 on chromosome 7p21. The terminal location is at the
right; the centrosomal end is on the left. For each patient’s row, black boxes indicate regions where all genotyped SNPs show LOH in the tumor
samples. Gray blocks indicate regions of uninformative SNPs in between observed regions of LOH. Unmarked areas of each sample indicate
informative SNPs where no LOH was observed. The dotted lines highlight the region covered by SOSTDC1. We note that three samples (two
Wilms and one RCC) show a large region of LOH that includes either the entire genotyped region (W-733 and W-8188) or a ~1 Mb region
including SOSTDC1 (RCC-614). LOH does not appear to center around a particular gene. The genes within this region of interest code for the
following proteins: transmembrane protein 195 (TMEM195); mesenchyme homeobox 2 (MEOX2); isoprenoid synthase domain containing (ISPD);
sclerostin domain-containing protein (SOSTDC1); ankyrin repeat and MYND domain-containing protein 2 (ANKMY2); basic leucine zipper and W2
domain-containing protein 2 (BZW2); tetraspanin-13 (TSPAN13); anterior gradient protein 2 homolog precursor (AGR2); anterior gradient protein 3
homolog precursor (AGR3); aryl hydrocarbon receptor precursor (AHR); and sorting nexin-13 (SNX13).
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tein’s role in modulating the cancer-relevant BMP and
Wnt signaling pathways, led us to hypothesize that LOH
within the SOSTDC1 locus may contribute to renal
tumor development.
We investigated the frequency of LOH within the
SOSTDC1 gene in pediatric Wilms tumors and adult
renal tumors. Overall, we observed LOH at the
SOSTDC1 gene in 4/25 (16%) of Wilms tumor patients.
This frequency is comparable to that of known Wilms
tumor suppressors WT1 and CTNNB1 [30-32]. The rate
of SOSTDC1 mutations observed in our studies was
somewhat higher than that reported by Ohshima and
coworkers (4/100;[10]). This disparity can potentially be
attributed to sample size limitations and/or experimental
variations. It should be borne in mind that current treat-
ment of Wilms tumors sometimes involves pre-surgical
chemotherapy or radiation. Differences in treatment sta-
tus within the patient population may have effects on
the resulting tissues used to obtain genomic DNA and
thus the results of the LOH studies.
LOH in Wilms tumors appears to occur in large sec-
tions on the short arm of chromosome 7, as seen in
patients W-733 and W-8188 (Figure 2). This is concor-
dant with previous studies [4,10,33,34]. Notably, two
patients (W-8194 and W-8197) showed examples of just
one instance of LOH each. Due to distances between
LOH markers for patient W-8194 (approximately 100
kb), and a lack of informative SNPs in SOSTDC1,i ti s
unclear whether this region of LOH extends beyond the
SOSTDC1 locus. Patient W-8197 showed one instance
of LOH in the direct sequence. As no other informative
SNPs were found within the direct sequence, this may
represent either LOH affecting SOSTDC1 or a point
mutation. It is noteworthy that tumor size, stage, histol-
ogy, and treatment status varied among these patients.
We observed LOH affecting the SOSTDC1 locus at a
f r e q u e n c yo f5 / 3 6( 1 4 % )i na d u l tR C C .I nc o n t r a s tt o
the observations within the Wilms tumors, the regions
of LOH in adult RCC tumors were noncontiguous, as
SNPs showing LOH were broken up by heterozygous
alleles. Due to the high incidence of aneuploidy in these
Table 1 Results of direct sequencing of SOSTDC1
Sample Location Informative SNPs
without LOH
Normal Tumor
RCC-129 End of Exon 1:
rs35324397
Yes A/G G
RCC-614 Beginning of Exon 1:
16,536,670; 16,536,667
between rs10240242 and rs35324397
Yes G/T, A/G T, A
RCC-614 Beginning of Exon 1:
16,536,641
between rs10240242 and rs35324397
Yes C/G C
RCC-614 End of Exon 1:
rs35324397
Yes C/G C
RCC-614 End of Exon 1:
5 bp downstream of rs35324397
Yes A/G G
RCC-635 Beginning of Exon 1:
16,536,641
between rs10240242 and rs35324397
Yes C/G C
RCC-737 Exon 5:
16,468,252
closest to rs6959246
Yes G/T T
W-733 Before Exon 1:
rs7781903
No C/T C
W-733 Beginning of Exon 1:
between rs10240242 and rs35324397
No C/G G
W-733 Beginning of Exon 2:
rs7801569
No C/T C
W-8188 Beginning of Exon 2:
rs7801569
No C/T C
W-8197 Exon 5:
16,468,252
closest to rs6959246
No G/T T
SNPs found in the direct sequences are summarized here. All other samples sequenced showed no LOH or other mutations. SNP location relative to sequenced
exons and chromosome 7 base pair location is provided. The existence of heterozygous SNPs (informative, but with no LOH present) in the sample is shown via
yes/no designation. RCC = adult renal carcinoma samples, W = pediatric Wilms tumors.
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chromosomal copy number variation. Indeed, multiple
studies referenced in the Database of Genomic Variants
show variations in copy number that affect parts of the
2 Mb region; including the area around SOSTDC1
[35,36].
We have previously reported downregulation of both
the message (90% of patients) and protein encoded by
SOSTDC1 in RCC-clear cell tumors [16]. To determine
whether or not these observations could be attributed to
LOH, we performed immunohistochemistry on the
patient samples that had displayed LOH at SOSTDC1.
We found that SOSTDC1 protein levels were compar-
able between samples that displayed LOH and those
that did not (Figure 3), indicating that the instances of
LOH observed in our patient samples were not asso-
ciated with a detectable decrease in SOSTDC1 protein
expression.
Considering previous observations that SOSTDC1
negatively regulates Wnt-induced signaling in renal
cells, we also tested whether SOSTDC1 LOH corre-
sponded to increased Wnt signaling in patient samples.
To this end, immunohistochemical analyses were under-
taken to compare SOSTDC1-relevant signaling between
samples with and without LOH. This staining showed
that LOH status did not consistently alter the levels or
localization of b-catenin, a marker of Wnt pathway acti-
vation (Figure 3).
The observations that LOH at SOSTDC1 did not
decrease SOSTDC1 protein expression or increase Wnt-
induced signaling suggest that LOH may not be the key
regulator of SOSTDC1 protein expression in pediatric
a n da d u l tr e n a lt u m o r s .W h i l eL O Hm a yp l a yar o l ei n
the regulation of this locus in some patients, other
mechanisms, including epigenetic regulation, must also
be considered. For example, promoter methylation has
been shown to have an important role in regulation of
the IGF2 gene [37-39] and loci at 11p13 and 11p15 in
Wilms tumors [16]. Improper splicing, a mechanism
that contributes to dysregulation of the Wilms tumor
suppressor gene WT1, might also contribute to the
observed downregulation of SOSTDC1 in kidney cancer
[37].
Although our limited sample size does not allow us to
definitively refute the hypothesis that LOH is the pri-
mary regulator of SOSTDC1 in pediatric and adult renal
tumors, we suggest that other modes of regulation must
also be considered. Future experiments that investigate
alternative regulatory mechanisms such as epigenetic
silencing of SOSTDC1 may uncover more pertinent con-
tributors to the reduced SOSTDC1 protein levels
observed in renal cancer.
Conclusions
This study investigates the role of SOSTDC1, a candi-
date renal tumor suppressor gene, in adult and pediatric
renal tumors. We observed within an analysis of the
Oncomine database that SOSTDC1 is expressed in nor-
mal renal tissue and that its expression is decreased in
adult and pediatric renal cancer. When adult renal cell
carcinoma samples were investigated for LOH within
SOSTDC1, we found that LOH was present in five of 36
adult renal carcinoma samples and four of 25 Wilms
tumors. This led us to investigate the possibility that
SOSTDC1 LOH correlates with reduced protein levels
or altered signaling. Our analyses did not reveal any
consistent correlations between SOSTDC1 LOH and
either SOSTDC1 protein levels or signaling. These find-
ings point to the possibility that SOSTDC1 downregula-
tion within adult and pediatric renal tumors may be
attributable to a mechanism other than LOH, such as
epigenetic silencing.
Additional material
Additional file 1: Map of the SOSTDC1 locus. Arrows indicate the
relative positions of designed primer pairs to potential regions of interest
within the SOSTDC1 gene. The sizes of the known and putative exons
are noted above the map; intron sizes are indicated below. The gene
translation start codon is in exon 3 and the stop codon is in exon 5. All
known coding sequences are contained within exons 3 and 5 (denoted
by black boxes). Putative exons 1, 2, and 4 are highlighted by gray
boxes. Data summarized from the Genome Browser hosted at UCSC.
Figure 3 Immunohistochemical analyses of SOSTDC1 and b-
catenin protein levels and localization. A) Pediatric Wilms tumor
samples and B) adult renal cell carcinoma samples with and without
SOSTDC1 LOH were stained with antibodies directed against
SOSTDC1 and b-catenin. No consistent staining differences were
observed between samples with LOH and those without.
Representative images are shown. Scale bar = 50 μm.
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Page 7 of 9Additional file 2: Primers for direct sequencing of SOSTDC1. Target
exon, forward (F) and reverse (R) primer sequences, and amplicon sizes
are shown. All primers designed to potential exons or regulatory regions
of SOSTDC1 and were optimized for 60°C reaction temperatures.
Additional file 3: Primers for loss of heterozygosity analysis by
single nucleotide polymorphism genotyping. Sequences of the
primers used for SNP LOH evaluation are shown. All primers designed for
use on the Sequenom MassARRAY platform. The percentage of
heterozygosity among informative SNPs within two populations from the
International HapMap Project are listed. (CEU = Utah residents with
Northern and Western European Ancestry; YRI = Samples from Yoruba
descent Ibadan, Nigeria; UEP = unextended primer).
Additional file 4: Characterization of SOSTDC1-specific antiserum.A )
A renal cell carcinoma sample with LOH at the SOSTDC1 locus was
treated with and without SOSTDC1 antiserum as an internal control to
demonstrate effective SOSTDC1 detection. B) Increasing amounts of
recombinant SOSTDC1 protein were gel-resolved and immunoblotted
with SOSTDC1 antiserum. C) Proteins from the breast carcinoma cell line
MDA-MB-231 and those from the breast epithelial cell line MCF10A were
resolved and immunoblotted with SOSTDC1-specific antiserum in the
presence or absence of competing peptide. The lack of banding in the
presence of the immunizing peptide demonstrates antibody specificity.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) protein levels were
used to verify loading. D) SOSTDC1 was purified from HEK-293 cells
transiently transfected to express FLAG epitope-tagged SOSTDC1 protein.
The coincident banding when membranes were probed with FLAG-
specific antibody and SOSTDC1-directed antiserum verifies the specificity
of the antiserum.
List of abbreviations
The following abbreviations were used: AGR2: anterior gradient protein 2
homolog precursor; AHR: aryl hydrocarbon receptor precursor; ANKMY2:
ankyrin repeat and MYND domain-containing protein 2; ATCC: American
Type Culture Collection; BMP: bone morphogenetic protein; bp: base pairs;
BZW2: basic leucine zipper and W2 domain-containing protein 2; CEU: Utah
residents with Northern and Western European Ancestry; CHTN: Cooperative
Human Tissue Network; DAB: 3,3’-diaminobenzidine; EDTA:
ethylenediaminetetraacetic acid; GAPDH: glyceraldehyde 3-phosphate
dehydrogenase; GST: glutathione S-transferase; IDT: Integrated DNA
Technologies; ISPD: isoprenoid synthase domain containing; kb: kilobase
pairs; LOH: loss of heterozygosity; Mb: megabase pairs; MEOX2: mesenchyme
homeobox 2; RCC: renal cell carcinoma; SDS: sodium dodecyl sulfate; SNP:
single nucleotide polymorphism; SNX-13: sorting nexin-13; SOSTDC1:
sclerostin domain containing 1; TMEM195: transmembrane protein 195;
TSPAN13: tetraspanin-13; UCSC: University of California, Santa Cruz; UEP:
unextended primer; W: Wilms’ tumor; Wnt: Wingless-Int; YRI: Samples from
Yoruba descent Ibadan, Nigeria.
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